tiprankstipranks
Trending News
More News >
KalVista Pharmaceuticals (KALV)
NASDAQ:KALV
Advertisement

KalVista Pharmaceuticals (KALV) AI Stock Analysis

Compare
512 Followers

Top Page

KALV

KalVista Pharmaceuticals

(NASDAQ:KALV)

Rating:45Neutral
Price Target:
KalVista Pharmaceuticals exhibits substantial financial challenges with weak revenue generation and profitability. While technical indicators show mixed momentum, the company's strategic agreement with Kaken Pharmaceutical provides a potential growth avenue. However, the negative P/E ratio and lack of dividend yield negatively impact valuation. Overall, the stock's score reflects financial struggles counterbalanced by strategic opportunities.
Positive Factors
Financial Stability
The company has a strong cash balance to support the launch of Ekterly, providing financial stability for future operations.
Market Expansion
Agreements have been entered into for the commercialization of Ekterly in Japan and Canada, expanding the drug's market reach.
Regulatory Approval
The FDA approved Ekterly as the first and only on-demand treatment for hereditary angioedema attacks.
Negative Factors
Formulary Inclusion
One KOL was skeptical that Ekterly would ever be broadly added to formularies, suggesting it may only be available through medical exception pathways—a process that could place a substantial documentation burden on physician practices.
Reimbursement Challenges
There is some noise on the burden of obtaining medical exceptions or difficulty in getting on formularies as payors might not see oral convenience.

KalVista Pharmaceuticals (KALV) vs. SPDR S&P 500 ETF (SPY)

KalVista Pharmaceuticals Business Overview & Revenue Model

Company DescriptionKalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of DME; sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks; KVD824, an oral product candidate for the treatment of HAE; and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. The company is headquartered in Cambridge, Massachusetts.
How the Company Makes MoneyKalVista Pharmaceuticals generates revenue through strategic partnerships, collaborations, and licensing agreements with larger pharmaceutical companies, which provide funding and resources to support its research and development activities. As a clinical-stage company, KalVista does not yet generate revenue from product sales but aims to do so upon successful development and commercialization of its product candidates. The company's financial performance is significantly influenced by milestone payments and royalties from successful partnerships, as well as potential future sales of approved therapies.

KalVista Pharmaceuticals Financial Statement Overview

Summary
KalVista Pharmaceuticals faces significant financial challenges with low revenue generation and profitability. The company has a modest gross profit margin but struggles with negative EBIT and net income. The balance sheet shows low leverage but is affected by continuous losses. Cash flow analysis indicates high cash burn and liquidity risks, highlighting the need for improved revenue streams and expense management.
Income Statement
20
Very Negative
KalVista Pharmaceuticals has faced significant challenges in generating revenue, with total revenue at $1.2 million in the TTM. Gross profit margin is modest at 63.26%, but the company is struggling with high negative EBIT and net income, leading to negative EBIT and net profit margins. The revenue growth is inconsistent, and the overall financial health from an income perspective is weak.
Balance Sheet
40
Negative
The balance sheet reveals a moderate debt-to-equity ratio of 0.04, indicating low leverage. However, the company has a negative return on equity due to continuous losses. The equity ratio stands at 52.58%, showing that over half of the assets are financed by equity, which is positive, but the company's financial stability is affected by ongoing losses.
Cash Flow
25
Negative
Cash flow analysis shows a negative operating cash flow of $127.6 million in the TTM, indicating cash outflows exceed inflows from operations, which is concerning. The company has a negative free cash flow and a weak cash flow to net income ratio, highlighting significant cash burn and potential liquidity risks.
BreakdownJun 2025Jun 2024Jun 2023Jun 2022Jun 2021
Income Statement
Total Revenue0.000.000.000.0012.69M
Gross Profit0.00-86.17M-802.00K-743.00K12.04M
EBITDA-173.33M-134.28M-92.11M-81.60M-45.59M
Net Income-183.44M-126.64M-74.85M-68.51M-44.49M
Balance Sheet
Total Assets250.77M235.40M183.20M203.88M272.01M
Cash, Cash Equivalents and Short-Term Investments187.65M210.40M149.38M166.20M248.93M
Total Debt6.31M7.32M8.23M8.19M5.91M
Total Liabilities155.38M28.82M22.18M18.79M14.82M
Stockholders Equity95.39M206.58M161.03M185.09M257.19M
Cash Flow
Free Cash Flow-152.91M-89.67M-76.46M-79.06M-30.25M
Operating Cash Flow-152.91M-89.23M-75.26M-78.13M-30.17M
Investing Cash Flow91.02M-84.72M41.41M57.86M-147.65M
Financing Cash Flow159.73M150.71M58.12M1.58M212.12M

KalVista Pharmaceuticals Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price13.31
Price Trends
50DMA
13.44
Negative
100DMA
12.76
Positive
200DMA
11.33
Positive
Market Momentum
MACD
0.02
Positive
RSI
42.98
Neutral
STOCH
6.93
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KALV, the sentiment is Neutral. The current price of 13.31 is below the 20-day moving average (MA) of 14.85, below the 50-day MA of 13.44, and above the 200-day MA of 11.33, indicating a neutral trend. The MACD of 0.02 indicates Positive momentum. The RSI at 42.98 is Neutral, neither overbought nor oversold. The STOCH value of 6.93 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for KALV.

KalVista Pharmaceuticals Risk Analysis

KalVista Pharmaceuticals disclosed 50 risk factors in its most recent earnings report. KalVista Pharmaceuticals reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

KalVista Pharmaceuticals Peers Comparison

Overall Rating
UnderperformOutperform
Sector (64)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
64
Neutral
€6.00B18.78-0.43%2.12%0.40%-34.51%
51
Neutral
$662.17M-28.73%189.31%51.03%
46
Neutral
$854.52M-26.25%68.93%
45
Neutral
$659.89M-121.50%-18.75%
45
Neutral
$852.27M-16.20%-9.46%
42
Neutral
$591.33M-62.58%4.28%
40
Underperform
$322.14M-60.45%6.99%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
KALV
KalVista Pharmaceuticals
13.31
0.52
4.07%
RCKT
Rocket Pharmaceuticals
3.07
-16.89
-84.62%
DNTH
Dianthus Therapeutics
21.50
-6.86
-24.19%
REPL
Replimune Group
5.71
-4.01
-41.26%
LENZ
LENZ Therapeutics
29.33
7.05
31.64%
GHRS
GH Research
13.44
1.99
17.38%

KalVista Pharmaceuticals Corporate Events

Product-Related AnnouncementsBusiness Operations and Strategy
KalVista Pharmaceuticals Signs Agreement with Kaken Pharmaceutical
Positive
Apr 8, 2025

On April 8, 2025, KalVista Pharmaceuticals entered into a License, Supply, and Distribution Agreement with Kaken Pharmaceutical for the commercialization of sebetralstat in Japan. This agreement includes an upfront payment of $11 million and potential milestone payments up to $24 million, plus royalties. Sebetralstat, if approved, would be the first oral on-demand treatment for HAE in Japan, marking a significant commercial opportunity for both companies.

Spark’s Take on KALV Stock

According to Spark, TipRanks’ AI Analyst, KALV is a Neutral.

KalVista Pharmaceuticals scores a 52.2, reflecting a blend of financial challenges and positive strategic moves. Significant weaknesses in financial performance and valuation are counterbalanced by strong technical momentum and promising corporate developments. Key risks include the company’s ongoing financial struggles, while the strategic appointment and technical indicators offer potential upside.

To see Spark’s full report on KALV stock, click here.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Apr 09, 2025